title: [Impact of anti-retroviral treatment with protease inhibitors on the evolution of cytomegalovirus retinitis in the patient carrying acquired immunodeficiency syndrome].
abstract: Up to now cytomegalovirus retinitis (CMVR) recurrence in AIDS patients was considered to be very high, even on maintenance therapy. Protease inhibitors (PI) are antiretroviral molecules which, with more efficacity than reverse transcriptase inhibitors, decrease viral charge and increase CD4's count aswell as survival. We analysed the impact of PI on CMVR evolution in a retrospective review of 18 patients with CMVR on maintenance therapy and PI treatment. In a first group, 13 patients started PI some time after CMVR diagnosis (median CD4 = 9/mm3). A second group of 5 patients developed CMVR (median CD4 = 63/mm3) after initiation of PI. In the first group, incidence of CMVR recurrences/1000 patients days was 6,45 (2323 patients days of follow-up (PDFU) before starting PI and 3,44 (4066 PDFU) after starting PI. In this group, during the follow-up's period of CD4's count inferior to 75/mm3, incidence of CMVR is 6,84/1000 patients days and becomes 0,86/1000 patients days during the follow-up's period of CD4's count superior to 75/mm3. In the second group, incidence of CMVR was 0/1000 patients days (1972 PDFU). In summary, incidence of CMVR decreases with PI's treatment. Interruption of CMVR maintenance therapy could be considered in patients with CD4's count higher than 75/mm3.
authors.affiliation: Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles.
authors.forename: L
authors.initials: L
authors.lastname: Postelmans
authors.forename: M
authors.initials: M
authors.lastname: Gerard
authors.forename: B
authors.initials: B
authors.lastname: Sommereijns
authors.forename: L
authors.initials: L
authors.lastname: Caspers
authors.forename: N
authors.initials: N
authors.lastname: Clumeck
authors.forename: J
authors.initials: J
authors.lastname: Libert
mesh_terms: D000328:Adult; D017726:Cytomegalovirus Retinitis / Q000209:etiology*; D018450:Disease Progression; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors